Trial Profile
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms POP-DURVA
- 09 Dec 2023 Planned number of patients changed from 200 to 195, as per Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium
- 09 Dec 2023 Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium
- 02 Jun 2023 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.